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Summary  Effective  antagonism  of  the  P2Y12 platelet  receptor  is  central  to  the  treatment
of acute  coronary  syndrome  (ACS)  patients,  especially  in  the  setting  of  percutaneous  coro-
nary intervention  and  stenting.  According  to  consensus  guidelines,  early  revascularization  and
intensive antiplatelet  therapy  are  key  to  reducing  the  complications  that  arise  from  myocar-
dial ischaemia  and  the  recurrence  of  cardiovascular  events.  Until  recently,  clopidogrel  was
the key  P2Y12 antagonist  advocated,  but  due  to  several  limitations  as  an  antiplatelet  agent,
newer drugs  with  more  predictable,  rapid  and  potent  effects  have  been  developed.  Prasugrel
and ticagrelor  are  now  the  recommended  ﬁrst-line  agents  in  patients  presenting  with  non-ST-
segment elevation  ACS  and  ST-segment  elevation  ACS,  due  to  large-scale  randomized  trials  that
demonstrated  net  clinical  beneﬁt  of  these  agents  over  clopidogrel,  as  stated  in  the  European
guidelines. Although  no  study  has  directly  compared  the  two  agents,  analysis  of  the  data  to
date suggests  that  certain  patient  types,  such  as  diabetics,  those  with  ST-segment  elevation
Abbreviations: ACS, acute coronary syndrome; ADP, adenosine diphosphate; AHA, American Heart Association; CABG, coronary artery
ypass graft; CI, conﬁdence interval; CYP, cytochrome P450; ESC, European Society of Cardiology; HPR, high on-treatment platelet reactivity;
R, hazard ratio; LD, loading dose; MD, maintenance dose; NSTEMI, non-ST-segment elevation myocardial infarction; NSTE-ACS, non-ST-
egment elevation acute coronary syndrome; PCI, percutaneous coronary intervention; STE-ACS, ST-segment elevation acute coronary
yndrome; STEMI, ST-segment elevation myocardial infarction; TIMI, Thrombolysis in Myocardial Infarction; UA, unstable angina.
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myocardial  infarction  or  renal  failure  and  the  elderly  may  have  a  better  outcome  with  one  agent
over the  other.  Further  studies  are  needed  to  conﬁrm  these  differences  and  answer  pending
questions  regarding  the  use  of  these  drugs  to  optimize  efﬁcacy  while  minimizing  adverse  events,
such as  bleeding.  The  aim  of  this  review  is  to  provide  an  overview  of  the  current  P2Y12 receptor
antagonists  in  the  treatment  of  ACS,  with  a  focus  on  issues  of  appropriate  agent  selection,
timing of  treatment,  bleeding  risk  and  the  future  role  of  personalized  treatment  using  platelet
function and  genetic  testing.
© 2014  Elsevier  Masson  SAS.  All  rights  reserved.
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Résumé  L’inhibition  effective  du  récepteur  plaquettaire  P2Y12 est  primordiale  dans  le  traite-
ment des  patients  présentant  un  syndrome  coronaire  aigu  (SCA),  en  particulier  lors  de
l’exécution  d’une  intervention  coronaire  percutanée  (ICP)  avec  pose  de  stent.  Selon  les  recom-
mandations,  une  revascularisation  précoce  et  un  traitement  antiplaquettaire  intensif  sont  clés
pour réduire  les  complications  secondaires  à  l’ischémie  myocardique  et  prévenir  la  récur-
rence d’événements  cardiovasculaires.  Jusqu’à  un  passé  récent,  clopidogrel  a  été  le  produit
de référence  pour  inhiber  le  récepteur  P2Y12,  cependant,  en  raison  d’un  certain  nombre  de
limitations de  son  action  antiplaquettaire,  de  nouveaux  agents,  plus  constants  dans  leur  effet,
plus rapides  et  plus  puissants,  ont  été  développés.  Prasugrel  et  ticagrelor  sont  maintenant
les molécules  de  première  ligne  recommandées  chez  les  patients  présentant  un  SCA  sans  sus-
décalage  du  segment  ST  (NSTE-SCA)  ou  avec  sus-décalage  du  segment  ST  (STE-SCA),  en  raison
de l’existence  de  larges  études  randomisées  ayant  démontré  un  bénéﬁce  clinique  net  de  ces
produits supérieur  à  clopidogrel,  comme  le  mentionnent  les  recommandations  européennes.
Bien qu’aucune  n’étude  n’ait  directement  comparé  les  deux  produits,  à  ce  jour  l’analyse  des
données  suggère  que  certains  proﬁls  de  patients,  comme  les  diabétiques,  les  patients  avec  un
STEMI, les  insufﬁsants  rénaux  ou  les  sujets  âgés,  tirent  plus  de  bénéﬁce  avec  l’une  ou  l’autre
des molécules.  Des  études  supplémentaires  sont  nécessaires  pour  conﬁrmer  ces  différences  et
répondre à  des  questions  restées  en  suspens  quant  à  l’utilisation  optimale  de  ces  produits,
consistant  à  favoriser  leur  efﬁcacité  tout  en  réduisant  leurs  effets  secondaires  tels  que  les
saignements.  Le  but  de  cette  revue  de  la  littérature  est  d’apporter  une  vue  d’ensemble  sur  les
molécules  actuelles  antagonistes  du  récepteur  P2Y12 dans  le  traitement  du  SCA,  en  insistant  sur
les problématiques  concernant  le  choix  approprié  de  la  molécule,  le  moment  de  son  adminis-
tration, le  risque  de  saignement  et  le  rôle  futur  d’un  traitement  personnalisé  grâce  aux  tests
de fonction  plaquettaire  et  génétiques.
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Introduction
Acute  coronary  syndromes  (ACSs)  have  a  signiﬁcant  impact
on  health  in  the  Western  world,  with  an  estimated  burden
of  1.5  million  hospitalizations  and  4.5  million  emergency
department  visits  per  year  attributed  to  ACSs  in  the  USA
[1].  Despite  advances  in  treatment,  ACSs  are  associated  with
signiﬁcant  morbidity  and  mortality.
In  an  ACS,  acute  atherosclerotic  plaque  rupture  leads
to  platelet  activation,  adhesion  and  aggregation,  which  are
vital  factors  in  the  early  formation  of  a  coronary  thrombus
[2].  Antiplatelet  agents  that  inhibit  agonism  by  adenosine
diphosphate  (ADP)  of  the  P2Y12 platelet  receptor  are  central
to  the  prevention  of  complications  and  recurrent  cardiovas-
cular  ischaemic  events  in  patients  with  ACS  and  also  post
percutaneous  coronary  intervention  (PCI)  [3—5]. Based  on
current  European  Society  of  Cardiology  (ESC)  and  American
Heart  Association  (AHA)  guidelines  [6—9],  the  diagnosis  of
ACS  is  further  substratiﬁed  into  ST-segment  elevation  ACS
(STE-ACS)  and  non-ST  segment  elevation  ACS  (NSTE-ACS).
Dual  antiplatelet  therapy  comprising  aspirin  and  a  P2Y12
antagonist  is  currently  recommended  for  the  treatment  of
this  clinical  presentation.
i
a
is  droits  réservés.
lopidogrel
lopidogrel  is  a  second-generation  thienopyridine  deriva-
ive  that  binds  speciﬁcally  and  irreversibly  to  the  platelet
2Y12 purinergic  receptor,  inhibiting  ADP-mediated  platelet
ctivation  and  aggregation  [10,11]. Clopidogrel  is  a  pro-
rug  that  is  metabolized  to  its  active  form  in  the  liver.
he  reactive  thiol  group  of  the  active  metabolite  of  clo-
idogrel  forms  a  disulphide  bridge  between  one  or  more
ysteine  residues  of  the  P2Y12 receptor.  This  interaction  is
rreversible,  accounting  for  the  observation  that  platelets
re  inhibited,  even  if  no  active  metabolite  is  detectable
n  plasma.  Until  recently,  clopidogrel  was  the  standard
f  care  in  dual  antiplatelet  therapy.  However,  clopidogrel
as  several  limitations  as  an  antiplatelet  agent.  Firstly,
t  has  a  delayed  onset  of  action,  which  results  in  sub-
ptimal  platelet  inhibition  at  the  time  of  urgent  or  early
CI.  Secondly,  the  platelet  inhibition  due  to  clopidogrel
s  irreversible  and  there  is  interindividual  variability  in
he  recovery  of  platelet  function,  leading  to  higher  bleed-
ng  risk  for  patients  undergoing  surgery,  including  coronary
rtery  bypass  graft  (CABG).  Thirdly,  there  is  considerable
nterindividual  variability  in  the  pharmacodynamic  response
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o  the  drug,  with  some  patients  being  termed  clopid-
grel  resistant  or  as  having  high  on-treatment  platelet
eactivity  (HPR).  This  is  largely  due  to  interindividual  dif-
erences  in  the  metabolism  of  the  prodrug  and  has  been
orrelated  with  increased  risk  of  atherothrombotic  events
12—15].
The  CURE  trial  was  the  key  landmark  analysis  that
xempliﬁed  clopidogrel  efﬁcacy.  In  this  study  of  12,562
atients  presenting  with  NSTE-ACS  within  24  hours  of  symp-
om  onset,  clopidogrel  300  mg  then  75  mg  and  aspirin
as  compared  with  aspirin  alone.  Clopidogrel  resulted  in
 20%  relative  risk  reduction  in  the  prevalence  of  the
rimary  composite  outcome  of  cardiovascular  death,  non-
atal  myocardial  infarction  (MI)  and  stroke  compared  with
spirin  monotherapy.  This  clinical  beneﬁt  was  also  shown
n  patients  presenting  with  ST-segment  elevation  myocar-
ial  infarction  (STEMI)  and  treated  with  thrombolysis  in  the
LARITY-TIMI  28  trial,  where  there  was  a  similar  reduction
n  the  occurrence  of  the  clinical  endpoint  of  cardiovascu-
ar  death,  myocardial  infarction  and  recurrent  ischaemia
16].
A  higher  loading  dose  (LD)  of  clopidogrel  was  assessed
n  ACS  patients  in  the  CURRENT-OASIS  7  trial,  where  600  mg
ere  administered  on  day  1,  150  mg  on  days  2—7  and  75  mg
hereafter  [17].  There  was  overall  no  beneﬁt  for  this  strat-
gy  with  respect  to  rate  of  occurrence  of  the  primary
utcome  of  cardiovascular  death,  myocardial  infarction  or
troke  after  30  days  (hazard  ratio  [HR]  0.94,  95%  conﬁdence
nterval  [CI]  0.83—1.06;  P  =  0.3).  There  was  however  a  signif-
cant  increase  in  the  rate  of  bleeding  in  the  high  double-dose
roup  (2.5%)  compared  with  in  the  low-dose  group  (2.0%)
HR  1.24,  95%  CI  1.05—1.46;  P  =  0.01).  In  a  subgroup  anal-
sis  of  17,263  patients  who  underwent  PCI,  the  high  dose
ppeared  to  have  beneﬁt  in  moderate-to-high-risk  patients
ndergoing  PCI,  signiﬁcantly  decreasing  the  occurrence  of
he  primary  composite  endpoint  of  myocardial  infarction,
troke  or  cardiovascular  death  at  30  days  (3.9%  vs.  4.5%;  HR
.86,  95%  CI  0.74—0.99;  P  =  0.039)  (Table  1).  Further  sup-
ort  for  these  ﬁndings  was  found  in  the  COMMIT  trial,  which
ncluded  a  large  number  of  patients  with  acute  myocardial
nfarction  (n  =  45,852)  and  demonstrated  that  75  mg  without
D  within  24  hours  of  presentation  produced  a  9%  propor-
ional  reduction  in  the  occurrence  of  death,  reinfarction  or
troke  [4].
ewer antiplatelet agents
o  overcome  the  sub-optimal  pharmacodynamic  and  phar-
acokinetic  proﬁle  of  clopidogrel,  new  P2Y12 inhibitors
ave  been  developed,  which  are  more  predictable  and
ave  a  faster  onset  of  action  —  characteristics  that  make
hem  particularly  attractive  for  PCI.  Prasugrel  and  tica-
relor  are  two  agents  that  are  now  recommended  for  the
reatment  of  NSTE-ACS  [6]  and  STEMI  [8]  based  on  evi-
ence  that  has  demonstrated  a  reduction  in  cardiovascular
vents  compared  with  clopidogrel.  Intravenous  agents  with
eversible  action,  such  as  cangrelor,  have  also  been  devel-
ped,  allowing  an  alternative  route  of  administration  and
ven  more  rapid  onset  and  offset  of  action  compared  with
ral  agents.
t
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rasugrel
rasugrel  is  a third-generation  thienopyridine  that  has  a  sim-
lar  mechanism  of  action  to  clopidogrel,  in  that  its  active
orm  binds  covalently  to  the  P2Y12 receptor  via  a  disul-
hide  bond,  causing  irreversible  blockade  for  ADP  binding.
owever,  it  has  much  more  rapid  and  consistent  inhibitory
ffects  on  platelet  aggregation  than  clopidogrel,  due  to
ore  efﬁcient  in  vivo  generation  of  its  active  metabolite
18]. The  prodrug  is  rapidly  hydrolysed  by  carboxylesterases
o  a  thiolactone,  which  is  then  efﬁciently  converted  to
he  active  derivative  via  cytochrome  P450  (CYP)  isoen-
ymes  (CYP3A4,  CYP2B6  and  CYP2C9)  in  a  one-step  process.
YP2C19  makes  only  a  minor  metabolic  contribution  [19].
he  esterase-mediated  step  for  prasugrel  occurs  mainly  in
he  intestine,  as  does  the  CYP-mediated  oxidative  step  lead-
ng  to  the  active  metabolite  formation.  However,  hydrolysis
f  clopidogrel  by  esterases  in  the  intestine  and/or  liver
eads  to  formation  of  an  inactive  metabolite,  and  conver-
ion  of  the  remaining  clopidogrel  to  its  active  metabolite
equires  two  CYP-mediated  steps  that  occur  mainly  in  the
iver.  The  polymorphisms  in  CYP2C9,  CYP2C19,  CYP2C17  and
BCB1  that  have  an  effect  on  clopidogrel  do  not  signiﬁcantly
lter  prasugrel  clinical  efﬁcacy,  pharmacokinetics  or  phar-
acodynamics  [20,21]. The  peak  concentration  of  the  active
etabolite  of  prasugrel  is  achieved  rapidly  at  30  minutes  and
 maximum  of  60—70%  inhibition  is  usually  achieved  within
—4  hours  [20].  For  the  STEMI  population,  recent  studies
ave  shown  that  optimal  inhibition  of  platelet  aggregation
s  reached  2—6  hours  after  LD  administration  [22]  and  rarely
efore  1  hour  [23].
The  ACAPULCO  trial  speciﬁcally  evaluated  the  pharma-
odynamic  effects  of  a 10  mg  maintenance  dose  (MD)  of
rasugrel  in  56  patients  with  unstable  angina  (UA)/non-
T-segment  elevation  myocardial  infarction  (NSTEMI),
ompared  with  a  high  MD  of  clopidogrel  (150  mg  daily)  after
 high  LD  (900  mg).  Greater  platelet  inhibition  with  prasug-
el  10  mg  daily  was  observed  over  14  days  compared  with
lopidogrel  150  mg  daily  [24].
The  pharmacodynamic  beneﬁt  of  prasugrel  was  further
emonstrated  in  the  OPTIMUS-3  study,  when  prasugrel  was
ompared  with  high-dose  clopidogrel  in  35  patients  with
ype  2  diabetes  mellitus  and  coronary  artery  disease.  Pra-
ugrel  was  associated  with  greater  platelet  inhibition  than
lopidogrel  at  4  hours  post  LD,  as  assessed  using  the  Veri-
yNow  assay  (least  squares  mean  89.3%  vs.  27.7%;  P  <  0.0001)
nd  this  was  also  seen  for  the  MD  at  7  days  (61.8%  vs.  44.2%;
 <  0.0001)  [25].
The  superior  antiplatelet  effect  of  prasugrel  was  further
emonstrated  in  the  phase  II  PRINCIPLE-TIMI  (prasugrel  in
omparison  to  Clopidogrel  for  Inhibition  of  Platelet  Acti-
ation  and  Aggregation  —  TIMI)  44  trial,  which  compared  a
0  mg  dose  of  prasugrel  with  a  600  mg  LD  of  clopidogrel.
mong  patients  planned  for  PCI,  loading  with  prasugrel
0  mg  resulted  in  greater  platelet  inhibition  than  a  clopid-
grel  600  mg  LD.  Daily  maintenance  therapy  with  prasugrel
0  mg  resulted  in  a  greater  antiplatelet  effect  than  clopid-
grel  150  mg  daily  [26].In  addition,  the  safety  of  prasugrel  was  demonstrated  in
he  JUMBO-TIMI  (Joint  Utilization  of  Medications  to  Block
latelets  Optimally  —  Thrombolysis  in  Myocardial  Infarction)
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Table  1 Comparison  of  endpoints  between  trials.
Endpoint
(percentage
of  events)
CURRENT-OASIS  7 TRITON-TIMI  38  (2007) PLATO  invasive  (2009)
Clopidogrel
600  mg
Clopidogrel
300  mg
HR (95%  CI) Prasugrel Clopidogrel
300  mg
HR (95%  CI) Ticagrelor Clopidogrel
300  mg
HR (95%  CI)
Primary  endpointa 3.90 4.50 0.86  (0.74—0.99) 9.90 12.10 0.81  (0.73—0.90) 9.00  10.70  0.84  (0.75—0.94)
All-cause  death 1.90 2.10 0.94  (0.76—1.16) 3.00 3.20 0.95  (0.78—1.16) 3.90  5.00  0.81  (0.68—0.95)
Non-fatal  myocardial
infarction
2.00 2.60 0.79 (0.64—0.96) 7.30 9.50 0.76  (0.67—0.85)  5.30  6.60  0.80  (0.69—0.92)
Non-CABG-related
major  bleedingb
0.80 0.60 1.34  (0.94—1.91) 2.40 1.80 1.32  (1.03—1.68) 2.80 2.20 1.23  (0.98—1.55)
CABG: coronary artery bypass graft; CI: conﬁdence interval; HR: hazard ratio.
a Death from cardiovascular causes, non-fatal MI, non-fatal stroke.
b According to Thrombolysis in Myocardial Infarction (TIMI) criteria.
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hase  II  trial.  This  was  a  dose-ranging  comparison  of  dif-
erent  prasugrel  doses  (7.5  mg,  10  mg  and  15  mg)  with
lopidogrel  [27].  At  30  days,  there  was  a  numerically  higher
ut  not  statistically  signiﬁcant  rate  of  bleeding  events
non-CABG  Thrombolysis  in  Myocardial  Infarction  [TIMI]
ajor  +  minor)  in  the  prasugrel  groups  than  in  the  clopido-
rel  group;  access  site  bleeding  was  the  most  common  type
f  bleeding  observed.
The  superior  pharmacodynamic  and  pharmacokinetic
roﬁle  of  prasugrel  has  translated  into  clinical  beneﬁt  com-
ared  with  clopidogrel.  The  TRITON-TIMI  38  trial  evaluated
3,608  patients  with  moderate-to-high-risk  ACS,  including
0,074  patients  with  UA  or  NSTEMI  and  3534  patients  with
TEMI  [28],  who  were  planned  to  undergo  PCI.  Patients  were
andomized  to  receive  a  prasugrel  60  mg  LD  followed  by
0  mg/day  or  clopidogrel  300  mg  followed  by  75  mg/day;  for
TEMI  patients,  the  study  drug  was  given  as  soon  as  possible,
eaning  that  prasugrel  could  be  given  without  knowledge  of
he  coronary  anatomy;  for  UA/NSTEMI  patients,  the  study
rug  was  given  when  the  decision  for  PCI  was  made  after
he  coronary  angiogram.  Patients  continued  therapy  for
—15  months  after  enrolment.  Prasugrel  was  associated
ith  a  19%  reduced  risk  of  occurrence  of  the  primary  end-
oint  (cardiovascular  death,  non-fatal  myocardial  infarction
r  non-fatal  stroke)  compared  with  clopidogrel  and  fewer
schaemic  events,  which  translates  to  a  number  needed  to
reat  of  46.  This  ischaemic  beneﬁt  was  counterbalanced
y  an  increased  risk  of  bleeding:  among  patients  treated
ith  prasugrel,  146  (2.4%)  had  at  least  one  TIMI  major  hae-
orrhage  that  was  not  related  to  CABG,  compared  with  111
1.8%)  patients  treated  with  clopidogrel  (hazard  ratio  1.32,
5%  CI  1.03—1.68;  P  =  0.03),  with  a  number  needed  to  harm
f  167;  thus,  the  overall  net  clinical  beneﬁt  of  prasugrel
as  signiﬁcant.  The  ischaemic  beneﬁt  was  mainly  driven  by
 reduction  in  myocardial  infarction  and  stent  thrombosis,
ith  overall  reductions  of  2.3%  and  1.3%,  respectively.  No
ifference  was  observed  in  mortality  (Table  1).
Based  mainly  on  the  outcome  of  the  TRITON  trial,  prasug-
el  was  approved  by  the  Food  and  Drug  Administration  (USA)
n  July  2009  and  by  the  European  Medicines  Agency  (Europe)
n  February  2009.
icagrelor
icagrelor  (AZD6140)  is  the  ﬁrst  of  a  new  class  of  antiplatelet
amily  called  cyclopentyl-trazolo-pyrimidines  (CPTPs)  and
s  also  the  ﬁrst  oral  reversible  selective  P2Y12 receptor
ntagonist.  Like  the  thienopyridines,  ticagrelor  binds  the
latelet  P2Y12 receptor  to  inhibit  the  prothrombotic  effects
f  ADP.  However,  unlike  the  thienopyridines,  this  effect
s  non-competitive  and  reversible.  Ticagrelor  appears  to
ct  through  an  allosteric  modulation  site  and  exhibits  a
onformational  change  in  the  receptor  by  binding  indepen-
ently  of  ADP;  it  therefore  does  not  prevent  ADP  binding
ut  seems  to  have  an  effect  on  ADP  receptor-induced
ignaling  and  platelet  aggregation  [29,30].  Ticagrelor  is  a
irect-acting  compound  and  does  not  require  metabolic  acti-
ation,  thus  obviating  any  inﬂuence  of  the  CYP  pathway  on
he  antiplatelet  response.  Moreover,  CYP2C19  and  ABCB1
enotypes,  which  are  known  to  inﬂuence  the  effects  of
lopidogrel,  did  not  inﬂuence  the  effect  on  ischaemic  out-
omes  in  ACS  patients.  When  administered  orally,  the  agent
m
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isplays  a  linear  pharmacokinetic  proﬁle  and  has  a  rapid
nset  of  action.  The  maximum  plasma  concentration  and
aximum  platelet  inhibition  are  reached  1—3  hours  after
reatment  [20]. However,  as  with  prasugrel,  for  the  STEMI
opulation,  recent  studies  have  shown  that  optimal  inhibi-
ion  of  platelet  aggregation  is  rarely  reached  before  1 hour
23]  and  that  the  effects  of  ticagrelor  and  prasugrel  on  inhi-
ition  of  platelet  aggregation  are  similar  [31].  Ticagrelor
as  a  relatively  short  half-life  and  an  offset  of  action  that  is
ore  rapid  than  clopidogrel,  so  it  may  be  advantageous  in
linical  scenarios  requiring  rapid  reversal  of  the  antiplatelet
ffect  (e.g.  in  patients  requiring  CABG).  However,  this  phar-
acodynamic  proﬁle  could  also  put  patients  at  risk  of  acute
vents,  such  as  stent  thrombosis,  especially  after  drug-
luting  stent  implantation  if  they  are  not  strictly  compliant
ith  therapy.
In  a  pharmacodynamics  substudy  of  the  PLATO  study  of  69
atients  with  ACS  (to  be  discussed  later),  ticagrelor  (180  mg
D,  90  mg  twice-daily  MD)  exhibited  greater  inhibition  of
latelet  aggregation  than  a standard  regimen  of  clopidogrel
300—600  mg  LD,  75  mg/day  MD)  within  the  ﬁrst  hours  after
D  and  after  28  days  of  maintenance  therapy  [32].
In  the  RESPOND  trial,  ticagrelor  was  shown  to  overcome
on-responsiveness  to  clopidogrel  in  patients  with  stable
oronary  artery  disease.  Patients  who  were  deemed  to  be
on-responders  to  clopidogrel  (n  =  41)  were  treated  with
icagrelor  (180  mg  LD/90  mg  twice  daily  MD)  and  high-dose
lopidogrel  (600  mg  LD/75  mg/day  MD)  in  a  14-day  two-way
rossover  design  [33].  Ticagrelor  treatment  resulted  in  a
igniﬁcantly  greater  reduction  in  platelet  aggregation  from
aseline  than  high-dose  clopidogrel.
Similarly  to  prasugrel,  ticagrelor  has  shown  clinical  bene-
t  in  head-to-head  phase  II  and  III  studies  with  clopidogrel  in
CS,  showing  decreased  incidence  of  adverse  cardiac  events
ith  a  higher  rate  of  non-CABG  related  bleeding  [33,34].
The  PLATO  study  was  the  largest  randomized  study  to
ompare  ticagrelor  with  clopidogrel.  In  total  18,624  patients
ith  ACS  were  included  and  randomized  to  either  ticagrelor
180  mg  LD,  90  mg  twice  daily  thereafter)  or  clopidogrel
300—600  mg  LD,  75  mg  daily  thereafter)  [28].  Treatment
egan  within  24  hours  of  symptom  onset  and  all  patients
ere  treated  with  aspirin  therapy.
At  12-month  follow-up,  there  was  a  16%  lower  rate  of
he  primary  composite  endpoint  of  cardiovascular  mortal-
ty,  myocardial  infarction  and  stent  thrombosis  in  patients
eceiving  ticagrelor  (9.8%  vs.  11.7%;  P  < 0.001),  which  trans-
ates  to  a  number  needed  to  treat  of  53.  This  improved
utcome  was  driven  by  lower  cardiovascular  mortality,
yocardial  infarction  and  stent  thrombosis.  Again,  this
schaemic  beneﬁt  was  balanced  by  increased  bleeding.
here  was  no  increase  in  overall  bleeding,  but  there  was
n  increase  in  major  non-CABG  related  bleeding  with  the
LATO  deﬁnition  (4.5%  vs.  3.8%,  respectively;  P  =  0.03)  and
he  TIMI  deﬁnition  (2.8%  vs.  2.2%;  P  =  0.025),  with  a  num-
er  needed  to  harm  of  167.  Although  this  trial  was  not
owered  for  mortality,  there  appeared  to  be  a  mortality
ate  beneﬁt  (4.5%  with  ticagrelor  vs.  5.9%  with  clopidogrel)
34].There  was  a  surprising  ﬁnding  of  increased  risk  of  pri-
ary  endpoint  in  ticagrelor-treated  patients  in  the  patients
nrolled  in  the  USA,  which  may  be  related  to  aspirin  doses
f  >  300  mg  in  this  patient  group  [35].
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In  a  pre-speciﬁed  analysis  of  PLATO,  ticagrelor  appeared
to  have  an  even  more  signiﬁcant  impact  in  chronic  kidney
disease  patients,  with  a  21%  reduction  in  occurrence  of  the
primary  endpoint  and  a  28%  reduction  in  mortality  without
a  signiﬁcant  increase  in  bleeding  [36].
Apart  from  unresolved  issues  regarding  differences  in
efﬁcacy,  ticagrelor  has  been  reported  to  have  a  propensity
to  elevate  uric  acid  and  creatinine  concentrations,  increase
ventricular  pauses  and  cause  dyspnoea.
Ticagrelor  received  regulatory  approval  in  Europe  in
December  2010  and  in  the  USA  in  July  2011.
Cangrelor
Cangrelor  belongs  to  a  family  of  ATP  analogues  that
are  relatively  resistant  to  the  breakdown  of  endonu-
cleotidases;  it  does  not  require  metabolic  activation  and
acts  as  a  reversible  competitive  antagonist  on  the  P2Y12
receptor.  Administered  intravenously  rather  than  orally,
cangrelor  has  a  short  half-life  of  <  5  minutes,  with  a  rapid
onset  of  effect,  inhibiting  platelets  to  a  high  degree,
and  a  quick  offset  of  effect  with  resolution  of  normal
platelet  function  within  an  hour  of  cessation  of  treat-
ment  [37—39].  With  this  pharmacokinetic  proﬁle,  the  major
use  for  cangrelor  is  in  the  acute  setting,  where  a  rapid
antiplatelet  effect  with  minimal  increase  in  bleeding  is
needed  (Table  2).
While  the  pivotal  trials  to  date  have  shown  a  satis-
factory  rate  of  major  bleeding  side  effects,  the  highly
potent  cangrelor  has  not  had  a  signiﬁcant  impact  on
the  occurrence  of  adverse  cardiac  events.  The  phase  III
CHAMPION-PCI  and  CHAMPION-PLATFORM  trials  compared
cangrelor  with  clopidogrel  600  mg  in  ACS  patients  sched-
uled  for  PCI,  with  the  timing  of  the  clopidogrel  dose
being  the  major  difference  between  the  trials  [40].  Both
trials  were  discontinued  prematurely  due  to  insufﬁcient
evidence  of  the  clinical  effectiveness  of  cangrelor.  There
were,  however,  reductions  in  stent  thrombosis  and  death
from  any  cause.  Furthermore,  the  lack  of  overall  demon-
strable  clinical  beneﬁt  of  cangrelor  may  be  related  to
the  deﬁnition  of  myocardial  infarction  used,  which  made
it  difﬁcult  to  adjudicate  early  ischaemic  events.  This
hypothesis  is  supported  by  a  pooled  analysis  of  the  two
trials,  using  the  universal  deﬁnition  of  myocardial  infarc-
tion,  which  showed  cangrelor  to  be  associated  with  a
signiﬁcant  reduction  in  early  ischaemic  events  compared
with  clopidogrel  in  patients  with  NSTE-ACS  undergoing  PCI
[41,42].
The  deﬁnition  of  myocardial  infarction  was  carefully
chosen  in  a  subsequent  trial  to  assess  cangrelor  —  the
CHAMPION-PHOENIX  study  [43,44].  This  was  a  random-
ized  double-blind  double-dummy  trial  that  compared
cangrelor  with  clopidogrel  standard  of  care  in  11,145
patients  who  had  not  previously  received  a  P2Y12 antag-
onist  and  required  PCI,  including  patients  with  stable
angina  and  ACS  (with  or  without  ST-segment  eleva-
tion).  The  primary  efﬁcacy  endpoint  was  a  composite  of
death,  myocardial  infarction,  ischaemia-driven  revascular-
ization  or  stent  thrombosis  at  48  hours  after  randomiza-
tion.
The  rate  of  occurrence  of  the  primary  efﬁcacy  endpoint
was  lower  in  the  cangrelor  group  than  in  the  clopidogrel
i
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roup  (4.7%  vs.  5.9%;  odds  ratio  0.78;  P  =  0.005),  driven  by
he  reduction  in  the  rate  of  acute  periprocedural  myocar-
ial  infarction  and  by  a  reduced  rate  of  stent  thrombosis
0.8%  vs.  1.4%;  P  =  0.01).  The  beneﬁt  from  cangrelor  was  con-
istent  across  several  pre-speciﬁed  subgroups,  apart  from
iabetic  patients,  who  represented  27.8%  of  the  global  pop-
lation,  (relative  risk  0.92  [0.67—1.27];  P  =  0.26).  The  rate
f  occurrence  of  the  primary  safety  endpoint  was  0.16%  in
he  cangrelor  group  versus  0.11%  in  the  clopidogrel  group
P  =  0.44).
Overall,  the  data  suggest  a  promising  role  for  cangrelor.
uture  studies  are  needed,  however,  to  determine  the  opti-
al  way  to  transition  ACS  PCI  patients  from  cangrelor  to
rasugrel  or  ticagrelor;  such  patients  represented  only  43%
f  patients  recruited  in  the  CHAMPION-PHOENIX  trial.
Due  to  its  rapid  on/off  effect,  cangrelor  also  has  potential
s  a  bridging  agent  in  patients  requiring  surgery,  by  ade-
uately  preventing  ischaemic  events  while  allowing  rapid
estoration  of  platelet  function  on  therapy  discontinuation
n  the  event  of  bleeding.  The  BRIDGE  study  evaluated  the
fﬁcacy  of  this  strategy  for  patients  taking  thienopyridine
ntiplatelet  agents,  such  as  clopidogrel,  who  are  scheduled
or  surgery.  A  total  of  210  patients  taking  thienopyridines
or  ACS  or  after  stent  placement,  who  were  awaiting  CABG,
ad  their  thienopyridine  stopped  and  were  then  randomized
o  either  cangrelor  (0.75  g/kg/min)  or  placebo  for  at  least
8  hours.  The  study  drug  was  discontinued  1—6  hours  before
ABG  surgery.  Patients  randomized  to  cangrelor  had  lower
evels  of  platelet  reactivity  throughout  the  treatment  period
ompared  with  placebo.  There  was  no  signiﬁcant  difference
n  major  bleeding  prior  to  CABG  surgery,  although  minor
leeding  episodes  were  numerically  higher  with  cangrelor.
ith  the  use  of  a  surrogate  endpoint  —  platelet  reactivity
s  the  primary  endpoint  —  the  ﬁndings  of  this  trial  must
e  interpreted  with  caution.  However,  it  does  demonstrate
he  potential  role  of  cangrelor  in  this  not  uncommon  set-
ing.
linical implications of novel agents
he  above-mentioned  trials  have  clearly  changed  experts’
pinions  and  this  is  reﬂected  in  both  the  ESC  and  the  Amer-
can  College  of  Cardiology  Foundation/AHA  guidelines  for
oth  STE-ACS  and  NSTE-ACS  [6—9].  The  European  guidelines
or  NSTE-ACS  recommend  that  a  P2Y12 inhibitor  be  added  as
oon  as  possible  to  aspirin  and  treatment  maintained  for  12
onths  [6].  Ticagrelor  (180  mg  LD,  90  mg  twice  daily)  is  rec-
mmended  for  all  patients  (including  those  pretreated  with
lopidogrel)  at  moderate-to-high  risk  of  ischaemic  events
e.g.  those  showing  elevated  troponins).  The  guidelines
dvocate  prasugrel  (60  mg  LD,  10  mg  daily  dose)  for  P2Y12
nhibitor-naive  patients,  especially  those  with  diabetes  mel-
itus,  in  whom  coronary  anatomy  is  known  and  who  are
roceeding  to  PCI,  unless  the  patient  shows  a high  risk  of
ife-threatening  bleeds.  The  ESC  NSTE-ACS  guidelines  rec-
mmend  that  either  ticagrelor  or  prasugrel  be  administered
n  preference  to  clopidogrel.
Similarly,  with  respect  to  the  treatment  of  STEMI  with  pri-
ary  PCI,  the  recent  2012  ESC  STE-ACS  guidelines  advocate
rasugrel  or  ticagrelor  over  clopidogrel.
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Table  2  Pharmacological  properties  of  P2Y12 antagonists.
P2Y12 receptor
inhibitors
Type  Administration  Action  Loading  dose;
maintenance
dose
Clopidogrel  Thienopyridine
(second
generation)
Oral Hepatic  transformation
in  active
metabolite/irreversible
blockade
300—600  mg;
75  mg
Prasugrel  Thienopyridine
(third  generation)
Oral Hepatic  transformation
in  active
metabolite/irreversible
blockade
60  mg;  10  mg
Ticagrelor
(AZD6140)
Cyclopentyl-
triazolo-
pyrimidine
Oral  Direct  and  reversible
inhibition;  competitive
binding
180  mg;  90  mg
twice  daily
Cangrelor
(ARC-669931MX)
ATP  analogue  Intravenous  Direct  and  reversible
inhibition;  competitive
30 g/kg;  bolus
4  g/kg/min  for
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ireatment of speciﬁc subgroups
o  trial  has  directly  compared  prasugrel  with  ticagrelor  and
igniﬁcant  differences  in  study  design  make  this  comparison
ifﬁcult.  The  design  of  PLATO  differs  from  TRITON-TIMI  38
n  two  important  ways.  Firstly,  the  proportion  of  patients
ith  NSTE-ACS  was  less  in  PLATO  (59.5%  and  59.3%  in  the
icagrelor  and  clopidogrel  arms,  respectively,  compared
ith  74%  in  the  TRITON  trial).  Secondly,  PLATO  studied  the
utcome  of  all  ACS  patients,  whether  pretreated  with  clo-
idogrel  or  not  and  whether  invasively  treated  by  PCI  or
ABG  or  medically  managed.  TRITON  studied  the  outcome
f  ACS  patients  undergoing  PCI:  in  STEMI  patients  treatment
as  initiated  as  soon  as  possible  after  the  index  event;  in
STE-ACS  patients  treatment  was  initiated  after  the  deci-
ion  for  PCI  [45].  However,  additional  analysis  of  the  pivotal
rials  is  possible  and  may  help  to  identify  preferential  targets
or  these  drugs.
Prasugrel  may  be  the  preferred  drug  in  patients  pre-
enting  with  STE-ACS  undergoing  PCI.  In  the  TRITON-TIMI
8  trial,  prasugrel  was  more  effective  than  clopidogrel  in
atients  presenting  with  STEMI  (10.0%  vs.  12.4%,  HR  0.79,
5%  CI  0.65—0.97;  P  =  0.02),  with  no  signiﬁcant  difference  in
leeding  risk  [45].
A  subgroup  analysis  of  TRITON-TIMI  38  reported  that  pra-
ugrel  signiﬁcantly  reduced  the  incidence  of  the  primary
ndpoint  compared  with  clopidogrel  among  non-diabetics
9.2%  and  10.6%,  respectively;  HR  0.86;  P  =  0.02)  and  dia-
etes  mellitus  patients  (12.2%  and  17.0%,  respectively;  HR
.70;  P  <  0.001,  P  interaction  =  0.09),  with  a  striking  number
eeded  to  treat  of  21  for  all  ACS  PCI  diabetes  melli-
us  patients.  Diabetes  mellitus  subjects  taking  insulin  also
ad  greater  beneﬁt,  with  a  reduced  incidence  of  the  pri-
ary  endpoint  compared  with  clopidogrel  (14.3%  and  22.2%,
espectively;  HR  0.63;  P  =  0.009),  than  those  not  taking
nsulin  (11.5%  and  15.3%,  respectively;  HR  0.74;  P  =  0.009).
on-diabetics  taking  prasugrel  were  more  likely  than  those
eceiving  clopidogrel  to  develop  major  haemorrhage  (2.4%
s.  1.6%,  HR  1.43;  P  =  0.02).  Rates  of  major  haemorrhage
ith  clopidogrel  and  prasugrel  were  similar  in  diabetes
p
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[binding 2—4  hours
ellitus  patients  (2.6  and  2.5%,  respectively;  HR  1.06;
 =  0.81,  P  =  0.29).  Therefore,  prasugrel  produced  a  greater
et  clinical  beneﬁt  (composite  of  all-cause  mortality,  non-
atal  myocardial  infarction,  non-fatal  stroke  or  non-fatal
IMI  major  bleeding  not  related  to  CABG)  than  clopidogrel
n  diabetes  mellitus  patients  (14.6%  vs.  19.2%;  HR  0.74;
 =  0.001)  than  in  those  without  diabetes  mellitus  (11.5%  and
2.3%,  respectively;  HR  0.92;  P  =  0.16,  P  =  0.05).
By  contrast,  in  the  PLATO  trial,  the  beneﬁt  of  ticagrelor
n  diabetes  mellitus  patients  was  consistent  with  the  overall
rial  results  but  did  not  reach  statistical  signiﬁcance  [46].
As  discussed  previously,  the  PLATO  trial  suggested  that
atients  with  chronic  renal  disease  in  particular  may  beneﬁt
rom  ticagrelor  treatment  [36].
Until  recently  there  has  been  a  lack  of  data  on  the  use  of
2Y12 inhibitors  in  the  treatment  of  patients  presenting  with
STE-ACS  who  are  selected  for  medical  management  with-
ut  revascularization.  The  recently  published  TRILOGY  trial
ttempted  to  address  this  issue  by  performing  a  randomized
ouble-blind  double-dummy  active-control  event-driven
rial  [47]. High-risk  NSTEMI  and  UA  patients  were  included
nd  treated  with  either  clopidogrel  or  prasugrel  from  within
0  days  of  presentation  up  to  30  months.  The  MD  of  pra-
ugrel  was  10  mg,  but  5  mg  in  elderly  patients  (aged  ≥  75
ears)  who  represented  23%  of  the  total  trial  population.
ccurrence  of  the  primary  efﬁcacy  endpoint  (cardiovas-
ular  death,  myocardial  infarction  or  stroke  in  patients
ged  <  75  years)  was  not  statistically  different  between  the
wo  arms  of  the  study.  Neither  was  statistical  signiﬁcance
chieved  for  other  efﬁcacy  endpoints,  including  cardiovas-
ular  death,  myocardial  infarction,  stroke,  all-cause  death,
ardiovascular  death  plus  myocardial  infarction,  recurrent
ospitalization  for  UA,  all-cause  death,  myocardial  infarc-
ion  or  stroke,  and  for  the  net  clinical  beneﬁt  endpoint,
ncluding  major  bleeding.
These  results  are  in  contrast  with  the  ﬁndings  of  a
re-speciﬁed  sub-analysis  of  the  PLATO  trial,  which  was  per-
ormed  in  a  population  half  the  size  of  the  TRILOGY-ACS
opulation,  with  a  shorter  follow-up  (median  9.2  months)
41]. Patients  treated  with  ticagrelor  had  lower  rates  of
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primary  composite  endpoint  (12.0%  vs.  14.3%;  HR  0.85,  95%
CI  0.73—1.00;  P  =  0.04)  and  mortality  (6.1%  vs.  8.2%;  HR
0.75,  95%  CI  0.61—0.93;  P  =  0.01).  However,  it  is  important  to
stress  that  there  was  24%  crossover  to  vascularization  dur-
ing  the  hospitalization  phase  in  the  PLATO  substudy  (versus
close  to  0%  in  TRILOGY-ACS)  and  40%  crossover  to  vascula-
rization  during  the  follow-up  period  in  the  PLATO  substudy
(versus  7.9%  in  TRILOGY-ACS)  [48,49].
Future role for clopidogrel?
With  the  advent  of  newer  P2Y12 antagonists,  the  ques-
tion  as  to  the  future  role,  if  any,  for  clopidogrel  in  the
acute  and  long-term  treatment  of  ACS  must  be  addressed.
Indeed,  the  newer  agents  are  now  recommended  as  ﬁrst
line  for  patients  presenting  with  moderate-to-high-risk  ACS.
However,  there  are  several  clinical  situations  where  clo-
pidogrel  may  be  preferable  to  these  agents.  Firstly,  for
low-risk  ischaemic  patients,  clopidogrel  remains  the  pre-
ferred  choice.  Secondly,  for  patients  with  a  high  bleeding
risk  or  on  concomitant  oral  anticoagulant  therapy,  the  cur-
rent  guidelines  advocate  short-duration  triple  therapy  and
that  the  P2Y12 agent  be  clopidogrel  [6,9].  Thirdly,  generic
clopidogrel  is  considerably  cheaper  and  so  may  temper
enthusiasm  for  these  newer  agents  in  real-life  practice.
However,  in  a  cost  analysis  comparing  clopidogrel  with
prasugrel,  prasugrel  remained  an  economically  dominant
strategy:  if  a  hypothetical  generic  cost  for  clopidogrel  of  $1
per  day  is  used,  the  incremental  net  cost  with  prasugrel  is
$996  per  patient,  yielding  an  incremental  cost-effectiveness
ratio  of  $9727  per  life-year  gained  [50].  Furthermore,  a
group  of  31  patients  was  switched  from  prasugrel  10  mg  to
clopidogrel  75  mg,  resulting  in  an  increased  rate  of  HPR  from
0%  with  prasugrel  to  29%  with  clopidogrel.  Early  switching
from  prasugrel  10  mg  to  clopidogrel  75  mg  reduces  the  num-
ber  of  patients  with  low  on-treatment  platelet  reactivity
and  minor  bleeding  events  but  unmasks  a  group  of  non-
responders  to  clopidogrel  with  unknown  consequences  for
clinical  outcomes  [51].
Personalized treatment
The  concept  of  personalized  treatment,  based  on  platelet
reactivity  assessment  with  bedside  monitoring  assays  and
genotyping  with  rapid  genetic  testing  platforms,  has  been
the  subject  of  much  debate  recently.  HPR  is  well  established
as  an  independent  predictor  of  increased  cardiovascular
events  [52].  The  factors  related  to  variability  of  response
to  clopidogrel  can  broadly  be  divided  into  four  categories:
environmental,  cellular,  clinical  and  genetic  factors  [53].
Genetic  variability  in  drug  absorption  and  metabolism
is  a  key  factor  responsible  for  the  inefﬁcient  generation
of  the  active  drug  metabolite.  The  two-step  hepatic  CYP-
dependent  oxidative  metabolism  of  the  prodrug  appears
to  be  of  particular  importance.  Pharmacogenomic  analyses
have  identiﬁed  loss-of-function  variant  alleles  of  CYP2C19,
speciﬁcally  the  2C19*2  allele,  to  be  the  predominant  genetic
mediators  of  the  antiplatelet  effect  of  clopidogrel  [54].
Several  trials  have  assessed  whether  this  risk  factor  is
modiﬁable  to  improve  clinical  outcome  with  the  adjustment
S
A
F185
f  P2Y12 antagonist  therapy  in  patients  with  poor  metabolic
esponse  to  clopidogrel.  The  randomized  data  so  far  have
een  neutral.  The  TRIGGER  PCI  trial  was  the  ﬁrst  to  evaluate
his  by  randomizing  stable  coronary  artery  disease  patients
ith  HPR  after  undergoing  PCI  to  either  prasugrel  10  mg  daily
r  clopidogrel  75  mg  daily.  The  trial  was  discontinued  due
o  a  low  event  rate  [55].  The  GRAVITAS  study  followed  and
xamined  the  efﬁcacy  of  double-dose  clopidogrel  (150  mg
aily)  in  a  similar  low-risk  post  PCI  population  [56].  This
ersonalized  strategy  did  not  affect  clinical  outcome,  which
ay  have  been  related  to  the  inadequate  treatment  of  HPR
y  double-dose  clopidogrel.  Finally  the  randomized  ARC-
IC  trial  included  a higher-risk  population,  tested  for  both
spirin  and  clopidogrel  resistance  and  offered  several  alter-
ative  treatments  for  HPR,  with  follow-up  platelet  function
esting  to  ensure  adequate  response  [57].  Despite  this  trial
esign,  there  was  no  statistical  difference  in  cardiovascu-
ar  events  between  the  monitoring  versus  the  conventional
reatment  arm  but  there  was  a  trend  towards  lower  bleed-
ng  events.  The  conclusion  that  can  be  drawn  from  these
rials  is  that  platelet  function  monitoring  cannot  be  rec-
mmended  routinely  in  the  general  PCI  population  or,  at
east,  that  stable  coronary  patients  might  not  beneﬁt  from
 platelet  function  test.  However,  platelet  function  mon-
toring  may  have  a role  in  selected  groups,  such  as  those
ith  stent  thrombosis  or  bleeding  events,  and  it  is  needed
o  pursue  research  on  platelet  function  testing,  especially
n  ACS  patients.  In  the  area  of  ACS,  we  are  now  waiting  for
he  results  of  the  ANTARCTIC  (NCT01538446)  study,  which  is
valuating  the  value  of  a  platelet  function  test  in  the  ACS
lderly  population,  with  a  focus  on  bleeding  events.
onclusions
espite  advances  made  in  the  treatment  of  ACS,  a  signiﬁcant
umber  of  patients  will  have  recurrent  ischaemic  events  on
urrent  dual  antiplatelet  therapy,  highlighting  the  need  for
mprovement  of  current  therapies.  Newer  agents  have  been
eveloped  to  overcome  the  shortcomings  of  clopidogrel  as
 P2Y12 antagonist  and  the  pivotal  trials  to  date  have  shown
hat  prasugrel  and  ticagrelor  in  particular  improve  outcome.
t  is  now  emerging  that  there  are  differences  in  efﬁcacy
etween  these  two  agents,  which  should  allow  clinicians
o  better  tailor  treatment.  Further  studies  are  indicated  to
irectly  compare  these  agents  and  also  to  assess  novel  intra-
enously  administered  agents,  such  as  cangrelor.  The  role
f  platelet  function  and  genetic  testing  in  subpopulations
s  tools  to  prevent  bleeding  events  with  these  more  potent
gents  is  yet  to  be  established.
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